This is analogous to the use of MEK inhibitors with BRAF targeted therapy in melanoma, a setting where drug addiction has been reported35, underscoring the continued importance of defining avenues of trametinib resistance in LUAD. This evidence concerns the gene MAP2K7 and melanoma.